Archive · 12 Aug 2025
Zydus Lifesciences Q1 Revenue Up 6%, Net Profit Rises
Zydus Lifesciences made more money this past quarter.
Their sales increased by 6% to ₹6,573 crore, and their profits went up by 3% to ₹1,466 crore.
They are doing well in India and the US.
The company is also focusing on selling more medicines that are similar to existing ones in the US.
They bought some factories in the US to help them make these medicines.
Zydus is also exploring new areas for growth such as medtech.
Zydus Lifesciences reported a 6% year-on-year revenue increase to ₹6,573 crore in Q1.
Net profit for the quarter was ₹1,466 crore, a 3% increase.
India business grew 8% driven by chronic therapies and portfolio expansion.
US business, the largest revenue driver, grew 2.9% year-over-year.
Company is expanding into biosimilars and acquired manufacturing facilities in the US.
- Who
- Zydus Lifesciences.
- What
- Zydus Lifesciences' financial results for Q1.
- When
- June quarter.
- Where
- Primarily in India and the US.
- Why
- To understand the company's financial performance.
- Revenue (Q1)
- ₹6,573 crore
- Revenue Growth (YoY)
- 6%
- Net Profit (Q1)
- ₹1,466 crore
- Profit Growth (YoY)
- 3%
- India Business Growth (YoY)
- 8%
- US Business Growth (YoY)
- 2.9%
Sources
Growth prescription: The future is specialty; Sun Pharma, Dr Reddy’s, Cipla lead, says Nomura
25% Donald Trump tariff likely to weigh on pharma margins: Analysts
Top-line momentum helps Zydus Lifesciences clock 3% growth in net profit for Q1 FY26
